1.26  0.28 (28.57%)		12-08 15:58
Open: 1.02 High: 1.27 Volume: 28,770		Pre. Close: 0.98 Low: 1.02 Market Cap: 15(M)

Short term
Mid term
Targets	6-month :	1.84	1-year :	2.3
Resists	First :	1.58	Second :	1.97
Pivot price	1.17
Supports	First :	0.94	Second :	0.79
MAs	MA(5) :	1.03	MA(20) :	1.29
	MA(100) :	1.95	MA(250) :	0
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	18.2	D(3) :	7.6
RSI	RSI(14): 47.8
52-week	High :	4.94	Low :	0.94

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AZTR ] has closed below upper band by 38.9%. Bollinger Bands are 8.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.27 - 1.28	1.28 - 1.28
Low:	1.01 - 1.01	1.01 - 1.02
Close:	1.25 - 1.26	1.26 - 1.27

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Mon, 16 Oct 2023
Azitra to Present at the ThinkEquity Conference - Business Wire

Mon, 14 Aug 2023
Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates - PR Newswire

Wed, 19 Jul 2023
Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors - PR Newswire

Tue, 11 Jul 2023
Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer - PR Newswire

Wed, 21 Jun 2023
Azitra, Inc. Announces Closing of Initial Public Offering - PR Newswire

Tue, 20 Jun 2023
Branford-based Azitra aims to raise $7.5M in IPO - Hartford Business Journal

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: ASE
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.